Acalabrutinib and Duvelisib for the Treatment of Relapsed/Refractory Indolent Non-Hodgkin Lymphoma

NCT04836832 · clinicaltrials.gov ↗

PHASE1

Phase

WITHDRAWN

Status

OTHER

Sponsor class

Stopped PI decision

Conditions

Recurrent Follicular Lymphoma
Recurrent Marginal Zone Lymphoma
Recurrent Nodal Marginal Zone Lymphoma
Recurrent Splenic Marginal Zone Lymphoma
Refractory Follicular Lymphoma
Refractory Indolent Non-Hodgkin Lymphoma
Refractory Marginal Zone Lymphoma
Refractory Nodal Marginal Zone Lymphoma
Refractory Splenic Marginal Zone Lymphoma

Interventions

DRUG: Acalabrutinib
DRUG: Duvelisib

Sponsor

Narendranath Epperla